Headlines about Microbot Medical (NASDAQ:MBOT) have trended somewhat positive this week, according to Accern. Accern scores the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Microbot Medical earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.07541802231 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Shares of Microbot Medical (MBOT) traded up $0.02 on Thursday, hitting $1.07. The stock had a trading volume of 473,800 shares, compared to its average volume of 993,300. The firm has a market capitalization of $40.92, a price-to-earnings ratio of -1.55 and a beta of -0.41. Microbot Medical has a 52 week low of $1.00 and a 52 week high of $9.94.
In related news, Director Yoseph Bornstein sold 35,000 shares of the stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $1.06, for a total value of $37,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 372,990 shares of company stock valued at $406,894 in the last quarter. 31.83% of the stock is currently owned by corporate insiders.
WARNING: “Microbot Medical (MBOT) Earns Media Impact Score of 0.19” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/11/microbot-medical-mbot-receiving-somewhat-favorable-press-coverage-study-shows.html.
Microbot Medical Company Profile
Microbot Medical Inc, formerly StemCells, Inc, is a medical device company. The Company specializes in the researching, designing, developing and commercializing transformational micro-robotic medical technologies leveraging the artificial and natural lumens within the human body. It is engaged in developing its two product candidates: the Self Cleaning Shunt (SCS) for the treatment of hydrocephalus and normal pressure hydrocephalus (NPH), and TipCAT, a self-propelling, semi-disposable endoscope that the Company is developing for use in colonoscopy procedures.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.